GZMB and neoplasm: After being released, it can bind with its specific receptor, namely CCR8, on peripheral Tregs and attract them to tumor sites where it induces a STAT3-dependent elevation of granzyme B level that would confer Tregs with a powerful weapon against their targets (29).